Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Assets (2016 - 2025)

Vistagen Therapeutics' Current Assets history spans 12 years, with the latest figure at $63.2 million for Q4 2025.

  • For Q4 2025, Current Assets fell 29.68% year-over-year to $63.2 million; the TTM value through Dec 2025 reached $63.2 million, down 29.68%, while the annual FY2025 figure was $82.1 million, 31.98% down from the prior year.
  • Current Assets for Q4 2025 was $63.2 million at Vistagen Therapeutics, down from $78.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $128.1 million in Q4 2023 and bottomed at $11.6 million in Q2 2023.
  • The 4-year median for Current Assets is $89.9 million (2024), against an average of $85.2 million.
  • The largest annual shift saw Current Assets skyrocketed 6488.88% in 2021 before it crashed 39.81% in 2025.
  • A 4-year view of Current Assets shows it stood at $86.8 million in 2021, then surged by 47.65% to $128.1 million in 2023, then dropped by 29.8% to $89.9 million in 2024, then fell by 29.68% to $63.2 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Current Assets are $63.2 million (Q4 2025), $78.9 million (Q3 2025), and $66.7 million (Q2 2025).